Tag Archive for: CSO

Nucleome Therapeutics appoints experienced biotech executive Dr. Michelle Morrow as Chief Scientific Officer

/in

Brings deep expertise in immunology, oncology and pharmacology with a strong track record of advancing innovative pipelines through discovery and translation into the clinic Reflects growing momentum at Nucleome following nomination of first preclinical development candidate for lead candidate NTP464, which is progressing towards IND enabling studies  Oxford, UK, 16 February 2026 – Nucleome Therapeutics […]

Read more

Curve Therapeutics Co-Founder and CSO Professor Ali Tavassoli awarded the Royal Society of Chemistry’s Interdisciplinary Prize

/in

Awarded in recognition of excellence in research and innovation and contribution to scientific progress Reflects the revolutionary potential of Curve’s gene-encoded Microcycle® platform to unlock the therapeutic potential of intracellular targets Southampton, UK, 25 June 2025 – Curve Therapeutics (“Curve” or the “Company”), a private biotechnology company building a pipeline of innovative cyclic peptide and […]

Read more

Outrun Therapeutics expands leadership team with appointment of Matthew Fyfe as Chief Scientific Officer

/in

Brings extensive small molecule drug discovery, development, and clinical experience across multiple therapeutic areas Will drive application of Outrun’s novel, proprietary X-E3L platform for protein stabiliser discovery to develop a pipeline of high-quality drug candidates targeting E3 ligases Continues strong momentum following 2024 emergence from stealth with $10M seed financing Dundee, Scotland – 13 January […]

Read more

Commit Biologics to present data on its Bispecific Complement Engaging (BiCE™) platform at the 16th International Conference on Complement Therapeutics

/in

Commit Biologics is pioneering a novel approach to activating the complement component of the immune system to treat cancer and autoimmune diseases Poster to be presented on Commit’s Bispecific Complement Engaging (BiCE™) platform   Aarhus, Denmark, 10 June 2024 – Commit Biologics (“Commit”), a pioneer in the activation of the complement system to treat cancer […]

Read more

AMSilk appoints Gudrun Vogtentanz as Chief Scientific Officer

/in

Munich, 17 October, 2023: AMSilk GmbH (“AMSilk”), the world’s first industrial supplier of bio-based performance materials, today announces the appointment of Gudrun Vogtentanz as Chief Scientific Officer (CSO). Gudrun will be responsible for AMSilk’s protein and strain strategy as well as bridging science and business development. With many years of experience in biotechnology research, Gudrun has a […]

Read more